查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
A型血友病市场:KOL的洞察
市场调查报告书
商品编码
1728479

A型血友病市场:KOL的洞察

KOL Insight - Haemophilia A
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入分析了血友病A的治疗现状，重点在于现有疗法和创新研发管线产品。结合关键意见领袖的见解，对Hemlibra和Altuiiio等知名疗法的疗效、耐受性和剂量进行了评估。报告也探讨了新型基因疗法和双特异性抗体的变革潜力。全面了解影响治疗偏好的因素、新疗法面临的挑战以及不断发展的治疗方案。

关键问题解答

  • 血友病A的第一线和二线治疗方法有哪些？
  • 目前血友病A的治疗方法在疗效、耐受性和给药便利性方面有何比较？
  • 研发管线疗法必须具备哪些优点才能成为血友病A的首选治疗方法？
  • 目前使用的血友病A疗法和研发管线疗法在未来的使用情况预计会发生哪些变化？
  • 为了有效竞争，研发产品必须达到哪些疗效和耐受性终点？
  • 哪些研发产品最有前景？它们将如何影响当前的市场参与者？

领导品牌

  • Arhemo (concizumab)
  • Artsubio (efanesoctocog alfa)
  • ASC618 (CRISPR/Cas9编辑的hFVIII基因治疗药物)
  • BT200 (RNA调节剂/vWF抑制剂)
  • Dirloctocogene samoparvovec (SPK-8011)
  • Dirloctocogene fitelparvovec (PF-07055480/SB-525)
  • Hemlibra（艾美珠单抗）
  • Himpavzi（马斯塔西单抗）
  • Inno8 (NNC0442-0344 A)
  • Mim8 (NNC0365-3769 A)
  • NEXT-007 (RG-6512/RO-7589655)
  • Pevoctocogene camaparvovec (DTX201)
  • Qfitlia（fitiran）
  • Roxavian（valoctocogene roxaparvovec）

部分参加专家名单

  • 血液学家、圣路易斯血友病中心主任英国伦敦圣托马斯综合护理中心
  • 美国纽约西奈山医学中心血液学与肿瘤学系止血与血栓形成教授
  • 比利时布鲁塞尔圣吕克大学血液学主任、医学教授
  • 瑞典教学医院医学教授、血液学主任
  • 密西根州安娜堡密西根大学血友病和凝血障碍计画儿科医学主任、儿科和病理学教授
  • 加州洛杉矶南加州大学凯克医学院儿科教授、止血和血栓形成计画主任

方法

治疗趋势报告是透过对全球领先的关键意见领袖 (KOL) 就当前和未来治疗前景进行深入访谈而得出的在关键疾病领域。我们根据严格的筛选标准精心挑选关键意见领袖 (KOL)，这些标准包括全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都附有精心设计的讨论指南。这些指南由我们与关键意见领袖合作开发，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。每份报告发布后，我们会持续进行12个月的市场监测，及时提供来自关键意见领袖的重大新闻事件、市场变化和市场发展动态的更新。

报告特色

FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供详细且可操作的洞察。我们拥有深厚的行业知识，能够为您提供相关且有价值的洞察，帮助您掌握新兴趋势，有​​效应对复杂挑战。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家独家访谈和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个活跃疾病领域，汇集医生情报（包括 KOL 洞察和定量医生调查），以及行业专家对医疗事务、数位医疗、销售与市场营销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。

简介目录

This report offers a detailed analysis of the haemophilia A treatment landscape, highlighting both current therapies and innovative pipeline products. Insights from leading key opinion leaders assess the efficacy, tolerability, and administration of prominent treatments like Hemlibra and Altuviiio. This report also explores the transformative potential of emerging gene therapies and bispecific antibodies. Gain a comprehensive understanding of the factors influencing treatment preferences, the challenges new therapies face, and the evolving treatment algorithms.

Key Questions Answered:

  • 1. What are the preferred first-line and subsequent-line treatments for haemophilia A, and why?
  • 2. How do current haemophilia A treatments compare in terms of efficacy, tolerability, and ease of administration?
  • 3. What must pipeline therapies demonstrate to become the treatment of choice in haemophilia A?
  • 4. How is the use of current and pipeline haemophilia A products expected to change in the future?
  • 5. What efficacy and tolerability endpoints must pipeline products achieve to compete effectively?
  • 6. Which pipeline products are most promising, and how will they impact current market players?

Key Brands:

  • Alhemo (concizumab)
  • Altuviiio (efanesoctocog alfa)
  • ASC618 (CRISPR/Cas9-edited hFVIII gene therapy)
  • BT200 (RNA modulator/vWF inhibitor)
  • Dirloctocogene samoparvovec (SPK-8011)
  • Giroctocogene fitelparvovec (PF-07055480/SB-525)
  • Hemlibra (emicizumab)
  • Hympavzi (marstacimab)
  • Inno 8 (NNC0442-0344 A)
  • Mim8 (NNC0365-3769 A)
  • NXT-007 (RG-6512/RO-7589655)
  • Peboctocogene camaparvovec (DTX201)
  • Qfitlia (fitusiran)
  • Roctavian (valoctocogene roxaparvovec)

Partial List of Participating Experts:

  • Consultant Haematologist, Haemophilia Centre Director, St Thomas' Comprehensive Care Centre, London, UK
  • Professor of Hemostasis and Thrombosis, Division of Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
  • Professor of Medicine, Chef de Service - Service d'Hematologie chez Cliniques Universitaires Saint-Luc, Brussels, Belgium
  • Professor of Medicine, Director of Haematology at a teaching hospital, Sweden
  • Professor of Pediatrics and Pathology, Pediatric Medical Director, Hemophilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, MI
  • Professor of Pediatrics, Director, Hemostasis and Thrombosis Program, Keck School of Medicine of USC, Los Angeles, CA

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.